TTNP - Titan Pharmaceuticals, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD

Titan Pharmaceuticals, Inc.

400 Oyster Point Boulevard
Suite 505
South San Francisco, CA 94080
United States

Full Time Employees23

Key Executives

NameTitlePayExercisedYear Born
Dr. Marc RubinExec. Chairman295kN/A1955
Mr. Sunil BhonslePres, CEO, Principal Financial Officer & Director395kN/A1950
Dr. Katherine L. Beebe-DeVarney Ph.D.Exec. VP & Chief Scientific OfficerN/AN/A1961
Mr. Dane D. HallbergExec. VP & Chief Commercial OfficerN/AN/A1969
Jennifer KiernanExec. Assistant to CEO & Investor Communications CoordinatorN/AN/AN/A
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Titan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases. It develops products based on ProNeura, a proprietary long-term drug delivery platform that focuses primarily on the treatment for chronic diseases. The company offers Probuphine, a six-month buprenorphine implant for the maintenance treatment of opioid addiction in patients. It also develops ProNeura-Ropinirole, an implant to provide delivery of ropinirole, a dopamine agonist for the treatment of Parkinson's disease; and triiodothyronine, an implant for the treatment of hypothyroidism. Titan Pharmaceuticals, Inc. was incorporated in 1992 and is based in South San Francisco, California.

Corporate Governance

Titan Pharmaceuticals, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.